He has served as Chair at the Department of Nephrology of the Cliniques Universitaires Saint-Luc since 2003 and is currently a full clinical professor at UCLouvain. Dr. Jadoul s clinical activities focus on the follow-up of hemodialysis and CKD patients, and his main research interests include b2-microglobulin amyloid- osis, hepatitis C, and other complications (e.g., falls, bone fractures, sudden death) in hemodialysis patients, as well as cardiovascular complications after kidney transplantation and various causes of kidney disease (e.g., drug-induced). Dr. Jadoul has coauthored over 260 scienti c papers, most of them published in major nephrology journals. He is biographic and disclosure information www.kidney-international.org currently serving as a theme editor of Nephrology Dialysis Transplantation, and he is also a country co-investigator for the Dialysis Outcomes and Practice Patterns Study (DOPPS; 2001 present). In 2008, he received the international distin- guished medal from the US National Kidney Foundation. He was previously a member of the KDIGO Executive Committee (2010 2015) and the ERA-EDTA Council (2013 2016). Presently, Dr. Jadoul is a KDIGO Co-Chair. Consultancy: Astellas*, AstraZeneca*, Merck Sharp & Dohme*, Mundipharma*, and Vifor Fresenius Medical Care Renal Pharma* Expert testimony: Vifor Fresenius Medical Care Renal Pharma* Grants / research support: Amgen*, Janssen-Cilag*, Otsuka*, and Roche* Speaker bureaus: Amgen*, Menarini*, Merck Sharp & Dohme*, Mundipharma, and Vifor Fresenius Medical Care Renal Pharma* Travel: Amgen* and Sano * *Monies paid to institution. Wolfgang C. Winkelmayer, MD, MPH, ScD, is the Gordon A. Cain Chair of Nephrology and professor of medicine at Baylor College of Medicine in Houston, TX, USA. Dr. Winkelmayer received his medical degree (1990) from the Univer- sity of Vienna, Austria, and later earned a Master of Public Health in healthcare management (1999) and a Doctor of Science in health policy (2001) from Harvard University, Cambridge, MA, USA. 